Summary.-Subcutaneous growth of immunogenic chemically induced rat sarcomata and a hepatoma was restricted when cells were injected into syngeneic animals in admixture with MER. Rats rejecting mixed inocula were immune to further challenge with the same tumour. Growth of a chemically induced mammary carcinoma which lacks detectable immunogenicity was suppressed when low cell inocula were injected in admixture with MER or intact BCG organisms, although animals were not immdne to re-challenge. These studies indicate that clinically MER may be a suitable alternative to BCG for contact suppression of tumour growth or incorporation into tumour cell: adjuvant vaccines for active immunotherapy.
example, injection of tumour cells in admixture with viable BCG vaccine restricts growth of 3-methylcholanthrene (Mc) induced sarcomata of mice and rats Pimm, 1971, 1973a; Bartlett, Zbar and Rapp, 1972) , a rat epithelioma (Baldwin and Pimm, 1973b) , hepatomata induced in the guinea-pig with diethylnitrosamine (Zbar, Bernstein and Rapp, 1971; Bartlett and Zbar, 1.972) and in rats with 4-dimethylaminoazobenzene . Mixed inocula of tumour cells and BCG which fail to develop induce specific host immunity and can be used for active immunotherapy of subcutaneous growths of sarcomata and hepatomata in rats, mice and guinea-pigs (Baldwin and Pimm, 1973a; and to treat pulmonary tumour deposits of rat sarcomata (Baldwin and Pimm, 1973c) . In addition, intrapleural and intraperitoneal injection of BCG restricts growth of rat tumours transplanted into these sites (Pimm and Baldwin, 1975) , and the intravenous injection of BCG organisms into pulmonary tissue suppresses growth in the lungs of intravenously injected rat sarcoma cells and pulmonary metastases from a rat epithelioma (Baldwin and Pimm, 1973b, c) and primary rat hepatomata .
Clinically, suppression of tumour growth by this form of BCG contact therapy has so far been limited mainly to surface tumours, particularly melanoma (Morton et al., 1970; Bornstein et al., 1973; Pinsky, Hirshaut and Oettgen, 1973) . In addition, mixed inocula of malignant cells and BCG are being used for active immunotherapy of solid tumours and myelocytic leukaemia (Sokal, Aungst and Grace, 1973) . However, adverse side -effects occur in patients undergoing immunotherapy employing standard BCG vaccines containing a proportion of viable organisms (Pinsky et al., 1973; Hunt et al., 1973) . Clearly non-living, non-toxic mycobacterial materials capable of suppressing tumour growth will be needed for significant extension of this form of treatment in humans. The present studies with experimental rat tumours were carried out to assess the tumour suppressive property of the methanol extraction residue (MER) of BCG, originally described by Weiss and Wells (1960) . Its tumour suppressive properties when injected in admixture with cells of immunogenic sarcomata and a hepatoma have been examined, since these tumours are known to be suppressed when injected in admixture with intact BCG organisms (Baldwin and Pimm, 1973a; Potter homogenizer. The resulting suspension was stored at -20°C in 1 ml aliquots at a concentration of 1 mg dry wt/ml and sterilized by heating to 70(C for 15 min before use (Weiss, 1972 only 2/10 animals; tumour growth in these rats was markedly retarded so that after 25 days mean tumour diameter in control rats was approximately 3 cm whereas the tumours in treated animals were 0.5 and 1 0 cm mean diameters. In the second test with hepatoma D23 (Experiment 7) growth from 1 x 105 cells was completely suppressed in all (10/10) rats by admixture with 200 /,g of MER.
In similar tests with mammary carcinoma AAF 57, which lacks detectable immunogenicity, subcutaneous challenges with low cell inocula were suppressed by contacting with BCG percutaneous vaccine, or MER (Table II The methanol extraction residue of BCG (MER), originally described by Weiss and Wells (1960) is the residue from methanol extraction of phenol killed, acetone washed BCG organisms. Its physical and biological properties have recently been reviewed by Weiss (1972) . Predominant among its characteristics is the ability of MER, when injected by a variety of routes, to act as a general immunostimulant and suppress growth of a number of transplanted animal tumours. MER has the advantage, compared with intact BCG organisms, that it is nonliving and therefore non-infectious, it is not pyrogenic and only poorly induces tuberculin hypersensitivity even in guineapigs or humans. Clinically, MER is currently being used in the immunotherapy of myeloid leukaemia (Weiss, 1972) .
The present studies demonstrate that localized MER may exert a pronounced tumour suppressive effect, so that subcutaneous growth of immunogenic transplanted rat sarcomata and a hepatoma is restricted when cells are injected in admixture with MER and this leads to the development of a tumour specific host immunity. These observations are comparable with previous findings with viable BCG vaccine containing intact organisms Pimm, 1971, 1973a; (Baldwin and Pimm, 1971) .
In addition to suppressing growth of immunogenic tumours, BCG or MER in admixture with low cell inocula of the non-immunogenic chemically induced mammary carcinoma AAF 57 restricted subcutaneous tumour growth. Rats rejecting mixed inocula of cells and MER were not, however, subsequently immune to re-challenge with this tumour. In similar studies with a diethylnitrosamine induced guinea-pig hepatoma, Zbar et al. (1971) reported that mixed inocula of tumour cells and BCG failed to develop although this tumour was not demonstrably immunogenic by conventional immunization techniques. In contrast to the present findings, however, guinea-pigs rejecting these mixed inocula were subsequently immune to further challenge with the same hepatoma.
The present studies, demonstrating that MER contacted with tumour cells may suppress their growth, extends the number of non-living adjuvants available for clinical application of this type of treatment although MER may have advantages compared with other mycobacterial preparations. Heat killed BCG inhibits growth of murine sarcomata (Chung, Zbar and Rapp, 1973) , but it still elicits tuberculin hypersensitivity. Moreover it is not consistently tumour suppressive since it does not control growth of guinea-pig hepatomata (Zbar et al., 1971) . Radiation sterilized BCG has also been employed to suppress subcu-taneous and pulmonary growth of rat tumour cells , but again this material still induces tuberculin reactions and hepatic granulomata in the guinea-pig. In addition, cell wall fragments of BCG retain tumour suppressive properties of the intact organisms, but only if attached to the surface of oil droplets in aqueous emulsions (Zbar, Rapp and Ribi, 1972; Baldwin and Pimm, 1973d) . Weiss (1974) has recently reported that intralesional injections of MER into transplanted murine sarcomata and a guinea-pig hepatoma may restrict tumour development. Further tests are therefore in progress with rat tumours described in this paper to compare the tumour suppressive properties of MER with those of intact viable or radiation killed BCG. These include tumour suppression by intralesional injections; ability of intraperitoneally and intrapleurally injected organisms to control tumour growth at these sites; the influence of intravenously injected vaccine on pulmonary metastasis; and the use of mixed inocula of BCG and tumour cells for active immunotherapy of pulmonary and subcutaneous tumour deposits. However, the implication from the present studies is that MER can replace intact BCG organisms in these situations, and may therefore serve as a suitable mycobacterial preparation for clinical applications of this type of tumour therapy, hopefully without the adverse side-effects currently being encountered in immunotherapy with intact, living BCG.
